Aurobindo Expects To Be In Top Three For Immunology Biosimilar – Is It Xolair?
Pneumococcal Vaccine Filing In H2
Executive Summary
Aurobindo is aiming for a regulatory filing in FY24/25 of its first immunology biosimilar, potentially a version of Novartis/Roche’s Xolair. Meanwhile, a pneumococcal vaccine is expected to be filed in India in the second half of FY23.
You may also be interested in...
Russia Sanctions, China Lockdown To Pinch Globally With Higher Freight, API Costs
With the Shanghai lockdown extended, Russian vessels blacklisted and oil prices fluctuating, global freight rates are expected to increase further. Apart from a direct hit, pharma manufacturers will also feel the ripple effect as prices of raw materials like APIs increase. Scrip spoke to Indian industry to gauge the impact.
It’s Deal Time: Aurobindo on M&A, Divestment Path
What value do PE funds see in Aurobindo Pharma’s injectables business as the company looks for a partner? Why is Aurobindo looking for acquisitions in India as it sets a domestic revenue target of $133m in three years from the formulations business? Scrip takes a look.
Selexis And Generium Launch Omalizumab Biosimilar In Russia
Selexis and Generium have claimed the launch of an omalizumab biosimilar in Russia, with their Genolar version of Xolair marking the third biosimilar to be launched by the pair following development with Selexis’ SUREtechnology platform.